Loading…
No business profile yet.
Size Ever Supreme Bio Technology (6712.TWO) is a Taiwan Health Care company (Biotechnology) with a market value of $439M, the 494th largest of 687 Taiwan companies the cockpit tracks. Shares closed at NT$144.50 on 6 Nov 2026.
Performance Over six months the shares gained 8.8%, against -15.4% for the median peer and -3.4% for the Taiwan market (cap-weighted) — 3rd highest of 20 in its peer set.
Growth Revenue grew 13.3% over the last twelve months (peer median +6.3%); the operating margin is 46.9% (peer median -9.8%).
Valuation It trades at 28.6× forward earnings against a peer median of 24.8× (4th cheapest of 7).
Price implies For today's price to make sense, revenue must grow about 6% a year for seven years (Req g). Recent delivered growth is +71%, so the hurdle is -65 pp: the price already allows for a slowdown.
Capital Return on invested capital runs 9.7 points above its cost of capital (5.0% WACC).
Next results Next results expected around 18 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | NT$1.14B | NT$1.02B | NT$889M | NT$758M | NT$628M |
| Revenue growth | — | +14% | +17% | +21% | — |
| Gross profit | NT$892M | NT$711M | NT$597M | NT$466M | NT$396M |
| EBITDA | n/a | NT$462M | NT$452M | NT$370M | NT$319M |
| Net income | NT$464M | NT$429M | NT$367M | NT$539M | NT$201M |
| Free cash flow | n/a | NT$535M | NT$435M | NT$416M | NT$316M |
| Capital expenditure | n/a | NT$48.8M | NT$46.2M | NT$5.83M | NT$8.11M |
| Total debt | n/a | NT$38.7M | NT$2.84M | NT$5.90M | NT$17.9M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6712.TWO | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -9.7% | -14.5% | 6th highest of 21 |
| 6-month return | +8.8% | -15.4% | 3rd highest of 20 |
| Distance from 52-week high | -21.5% | -38.2% | highest of 21 |
| Revenue growth (TTM) | +13.3% | +6.3% | 7th highest of 18 |
| Operating margin | 46.9% | -9.8% | 4th highest of 18 |
| Forward P/E | 28.6× | 24.8× | 4th cheapest of 7 |
| Growth the price implies (Req g, 7 yrs) | 5.8% | 6.0% | 4th least demanding of 8 |
| Growth delivered (Del g) | +70.5% | +1.6% | highest of 7 |
| Hurdle (Req g minus delivered) | -64.7 pp | +18.5 pp | least demanding of 7 |
| ROIC minus cost of capital | +9.7 pp | -8.2 pp | 3rd highest of 17 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Ever Supreme Bio Technology 6712.TWO | Taiwan | $439M | +9% | +13% | 47% | 28.6× | 5.8% | +70.5% |
| TenNor Therapeutics Suzhou 6872.HK | Hong Kong | $440M | n/a | n/a | n/a | n/a | n/a | n/a |
| Wuhan Hiteck Biological Pharma 300683.SZ | China | $443M | -36% | -30% | -27% | n/a | n/a | n/a |
| Shanghai Shen Lian Biomedical 688098.SS | China | $444M | -18% | -17% | -16% | n/a | n/a | n/a |
| Qingdao Vland Biotech 603739.SS | China | $450M | -21% | +5% | 7% | 33.9× | 18.2% | +7.3% |
| Hubei Goto Biopharm 300966.SZ | China | $427M | -7% | +6% | -10% | n/a | n/a | n/a |
| EirGenix 6589.TW | Taiwan | $427M | +2% | +27% | -71% | n/a | n/a | n/a |
| Polynovo PNV.AX | Australia | $426M | -12% | +13% | 5% | 89.0× | 53.3% | +37.6% |
| TaiMed Biologics 4147.TWO | Taiwan | $454M | +10% | +4% | -30% | n/a | 31.8% | -3.3% |
| Steminent Biotherapeutics 7729.TWO | Taiwan | $458M | +139% | n/a | n/a | n/a | n/a | n/a |
| Arvinas ARVN | United States | $420M | -37% | -12% | -10% | n/a | n/a | n/a |
| Komipharm International 041960.KS | South Korea | $460M | -12% | -3% | 2% | n/a | n/a | n/a |
| Shanghai Obio Technology (Group) 688238.SS | China | $462M | -4% | +20% | -79% | n/a | n/a | n/a |
| Kamada KMDA | United States | $417M | -15% | +11% | 14% | 15.8× | 4.1% | +6.5% |
| Shattuck Labs STTK | United States | $464M | -33% | -67% | -5,571% | n/a | n/a | n/a |
| Qyuns Therapeutics 2509.HK | Hong Kong | $415M | -17% | +230% | 56% | 10.0× | -20.2% | n/a |
| CorMedix CRMD | United States | $415M | -33% | +280% | 47% | n/a | n/a | n/a |
| Eupraxia Pharmaceuticals EPRX.TO | Canada | $466M | -5% | n/a | n/a | n/a | n/a | n/a |
| Medigen Vaccine Biologics 6547.TWO | Taiwan | $467M | -5% | +44% | 10% | 187.6× | n/a | n/a |
| Jacobio Pharmaceuticals 1167.HK | Hong Kong | $468M | -27% | +286% | 68% | 6.3× | -14.9% | -36.1% |
| Shanghai ZJ Bio-Tech 688317.SS | China | $468M | -16% | -18% | -75% | n/a | 6.0% | -62.3% |